circadian clock raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
Reviewed 2026-05-06. Anything still debated is marked as such rather than presented as settled.
SR9009 is frequently discussed alongside other REV-ERB ligands, including synthetic agonists and natural heme-related molecules. Its selectivity for REV-ERB over related nuclear receptors has been measured in binding and reporter assays, though off-target activity at higher concentrations is possible. The compound is prohibited in sport by the World Anti-Doping Agency, and it is not approved for any medical use in major jurisdictions. Products sold online may be labeled as research chemicals, and their identity and purity are not guaranteed by regulatory review.
SR9009 is a synthetic small molecule that acts on the nuclear receptors REV-ERBα and REV-ERBβ. These receptors are part of the circadian clock machinery and normally repress transcription of certain target genes. In laboratory research, SR9009 is used as a chemical tool to study how REV-ERB activity influences metabolism, inflammation, and daily biological rhythms. The compound is not an approved medicine, and its effects in humans remain largely uncharacterized. It is often described as an investigational agent rather than a therapeutic product.
REV-ERB proteins typically suppress gene expression by recruiting corepressor complexes to DNA response elements. SR9009 binds these receptors and strengthens that repressive action in cell-based assays. Studies in rodents have reported changes in lipid handling, mitochondrial function, and exercise capacity after treatment. Such findings are often cited as evidence for metabolic effects, but species differences and limited pharmacokinetic data make direct translation to humans uncertain. Researchers continue to examine which effects are robust and which depend on specific experimental conditions.
At the molecular level, SR9009 binds the ligand-binding domain of REV-ERB and strengthens recruitment of corepressor proteins such as NCoR and HDAC3. This increases repression of target genes, including Bmal1 and other clock-controlled and metabolic genes. In rodent studies, such changes have been linked to altered lipid handling, glucose metabolism, and energy expenditure. The precise chain of events between receptor binding and whole-body effects remains an active area of research. Findings in animals do not automatically translate to humans.
Laboratory studies often administer SR9009 by injection because oral absorption appears poor in rodents. Reported pharmacokinetic properties include rapid metabolism and low systemic exposure after oral dosing. Human pharmacokinetic data are sparse, so absorption, distribution, metabolism, and excretion in people are not well defined. Some research explores related REV-ERB compounds with improved drug-like properties. Regulatory approval for any REV-ERB agonist as a human medicine has not been granted to date.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ, also called NR1D1 and NR1D2. These receptors help regulate circadian rhythms and metabolic gene programs. The compound was developed for laboratory research, not as an approved therapeutic. Its identity is distinct from steroid hormones and selective androgen receptor modulators. Scientific interest centers on how REV-ERB activation changes gene expression in cells and animal models.
| Property | Value | Notes |
|---|---|---|
| Common name | SR9009 | Also marketed informally as Stenabolic |
| Chemical class | Synthetic REV-ERB agonist | Binds REV-ERBα and REV-ERBβ |
| Molecular formula | C24H30ClN3O4S | Approximate molecular weight 492 g/mol |
| CAS Registry Number | 1379686-30-2 | Identifier for the parent compound |
| Regulatory status | Not approved for human use | Prohibited in sport by WADA |
Most published work on SR9009 consists of preclinical studies. It is widely sold as a research chemical, a category that does not imply safety, efficacy, or pharmaceutical-grade quality. Sports anti-doping organizations have listed SR9009 as a prohibited substance, and its presence in an athlete sample can lead to sanctions. Legal status differs by country; in several jurisdictions it is not approved for human consumption and may be treated as an unapproved new drug.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. It is not a steroid, peptide, or natural hormone. In scientific literature, it appears under the code SR9009 and in non-scientific contexts as Stenabolic. The compound was identified through chemical screening efforts aimed at targeting circadian clock components. Its status remains investigational, and no regulatory agency has approved it as a human medicine.
Handling practices for SR9009 focus on minimizing degradation and contamination. The solid is generally stored desiccated at or below -20 °C, protected from light and moisture. Stock solutions are often prepared in dimethyl sulfoxide or ethanol, then aliquoted to avoid repeated freeze–thaw cycles. Aqueous solubility is low, so formulations for animal studies may require cosolvents or suspending agents. Personnel should follow institutional chemical safety procedures, because toxicological data for humans are incomplete.
Regulatory status varies by country and intended use. Major drug agencies have not granted marketing authorization for SR9009 as a medicine, and it is not listed as a controlled substance in many jurisdictions. It is often sold as a research chemical, a category that may fall outside pharmaceutical manufacturing rules. Buyers should verify local laws and supplier documentation, including certificates of analysis. The lack of standardized quality controls raises concerns about identity, purity, and actual content in products marketed online.
Handling recommendations for SR9009 in a laboratory setting include storing the solid at low temperature, protected from light and moisture. The compound is often dissolved in dimethyl sulfoxide or ethanol for experiments. Solutions should be prepared with appropriate personal protective equipment and disposed of according to local rules. Stability data for long-term storage are limited, so stock solutions are typically kept cold and used within defined periods. Records of preparation date and concentration support reproducibility.
SR9009 is not approved as a medicine by major regulatory agencies. It is commonly sold as a research chemical, a category that may fall outside customary drug approval and quality rules. In sports, the World Anti-Doping Agency lists SR9009 as a prohibited substance. Athletes who use it can face sanctions if it is detected in a sample. Legal status varies by country, and importation may be restricted. Enforcement practices differ across borders.
SR9009 stability depends on temperature, moisture, light, and solvent. Solid material is generally kept cool and dry, while solutions may require protection from repeated warming and cooling. Degradation can appear as color changes, precipitate, or new chromatographic peaks. Researchers should follow supplier instructions and their own stability data. Long-term storage conditions for human use have not been established because the compound lacks approved clinical formulation.
SR9009 is supplied as a solid research chemical, often in milligram quantities. Laboratories typically weigh it in a controlled environment because fine powders can disperse. Stock solutions are commonly prepared in dimethyl sulfoxide and stored in small aliquots to reduce freeze-thaw cycles. Personal protective equipment and chemical fume hoods are standard when handling unknown or potent compounds. These practices address laboratory safety rather than human use.
Other advantages of the NPT approach are that it is fast and convenient, usually less painful, and offers, in home use, the ability for patients to measure their own INRs when required. Among its problems are that quite a steady hand is needed to deliver the blood to the exact spot, that some patients find the finger-pricking difficult, and that the cost of the test strips must also be taken into account. In the UK these are available on prescription so that elderly and unwaged people will not pay for them and others will pay only a standard prescription charge, which at the moment represents only about 20% of the retail price of the strips. In the US, NPT in the home is currently reimbursed by Medicare for patients with mechanical heart valves, while private insurers may cover for other indications. Medicare is now covering home testing for patients with chronic atrial fibrillation. Home testing requires a doctor's prescription and that the meter and supplies are obtained from a Medicare-approved Independent Diagnostic Testing Facility (IDTF). There is some evidence to suggest that NPT may be less accurate for certain patients, for example those who have the lupus anticoagulant.
Governor King had been requesting a replacement, for at least a year. In 1805, Governor William Bligh was appointed. Although the economy had developed and diversified somewhat by 1806, Bligh arrived determined to bring the Corps, and especially John Macarthur, to heel, and stop their trading in rum. This led to the Rum Rebellion, the deposing of Bligh, and the eventual recall of the New South Wales Corps. In 1808, the New South Wales Corps was renamed the 102d Regiment of Foot. Having arrived in the colony in December 1809 with the 73rd Regiment of Foot, which was to take over from the 102d Regiment of Foot, Governor Lachlan Macquarie was able to control the rum trade more effectively, introducing and enforcing a licensing system. Due to the lack of currency, he was still forced to pay for public works in rum. The construction of Sydney Hospital was entirely funded by granting a monopoly on the import of rum to the contractors, who were the merchants Alexander Riley and Garnham Blaxcell. The colonial surgeon D'Arcy Wentworth, and troops were used to prohibit the landing of rum anywhere but at the hospital dock. A few of the officers and long-serving privates in the 102d Regiment were transferred to Macquarie's 73rd regiment, bringing it up to near full strength. About 100 veterans and invalids were retained for garrison duty in New South Wales.
=== Toxicity === Just as selenomethionine can be randomly incorporated into proteins, selenocystine can also be mistakenly attached to tRNACys by cysteinyl-tRNA synthetase and incorporated into proteins in lieu of cystine. This causes considerable toxicity. A variant synthase that can distinguish between Cys and Sec helps reduce toxicity.
=== Vapour patch === In a vapour patch, the adhesive layer not only serves to adhere the various layers together but also to release vapour. Vapour patches release essential oils for up to 6 hours and are mainly used for decongestion. Other vapour patches on the market improve quality of sleep or aid in smoking cessation.
Sources: en.wikipedia.org
== Procedure == The exact methods of this procedure are not standardized and vary considerably, for example the exact number and locations of the injections and the volume of the injected material. Before the operation, antibiotic prophylaxis may be given. The rectum is prepared with a phosphate enema at least 2 hours before the procedure. The procedure can be carried out under local anesthetic on an out patient basis, or with caudal epidural anesthesia, or with intravenous sedation, or under general anesthesia. Ultrasound guidance may be used during the injections, which is sometimes reported as being more effective than the surgeon simply palpating (feeling) and looking where to inject. The site of the bulking material can be inter-sphincteric (in the space between the IAS and the EAS), submucosal injections (under the mucosal layer, usually just above the dentate line), or within the IAS itself. Injection of the material can be by the different routes: transanal route, trans-sphincteric, intersphincteric, perianal route (going through the muscle complex) or transcutaneous route. As such, there are several different variations of injection location and route:
The petition seeks to have the risk of serious sexual side effects persisting after discontinuation mentioned in the product labels of SSRIs and SNRIs. The lawsuit was dismissed by the United States District Court for the District of Columbia on March 25, 2025, due to the plaintiff lacking legal standing, as the court found no specific informational or physical injury. The FDA has not mandated comprehensive PSSD warnings across all SSRI and SNRI labels, though fluoxetine (Prozac) has included a warning about persistent sexual side effects since 2011. Most other SSRI and SNRI labels address sexual dysfunction during use but not explicitly after discontinuation.
=== Extracellular vesicle cross-talk === Recent studies have highlighted the involvement of RAGE (Receptor for Advanced Glycation End-products) in mediating the intercellular communication through extracellular vesicles (EVs), particularly during inflammatory responses. RAGE, known for its interaction with various ligands including advanced glycation end-products (AGEs), plays a key role in the biogenesis and secretion of EVs from stressed or damaged cells. Extracellular vesicles, such as exosomes, are small lipid-bound vesicles that facilitate cell-to-cell communication by transferring molecular cargo including proteins, lipids, and RNAs between cells. Recent evidence suggests that RAGE-associated vesicular pathways contribute to the exacerbation of inflammation by enabling pro-inflammatory signaling between cells. Specifically, a study from 2023 demonstrated that β-cells exposed to cytokine-induced stress release EVs enriched with RAGE ligands, which were found to further activate RAGE signaling pathways in neighboring cells, promoting inflammatory responses and impairing insulin secretion. These EV-mediated effects were shown to propagate inflammation across multiple cell types, indicating that RAGE-associated vesicles may play a pivotal role in amplifying the immune response in metabolic disorders like diabetes. Another study from 2024 reported that EVs containing RAGE ligands could be detected in the bloodstream of patients with early-stage diabetes, suggesting the potential utility of these vesicles as biomarkers for early diagnosis of inflammatory diseases.
Novel ingredients must undergo scientific assessment before being considered safe for consumption, and a safety assessment report must be completed for ingredient authorization. In addition, all pet food animal products must be considered fit for human food consumption, a measure put into place to prevent the spread of zoonotic diseases, and plants that will be manufacturing the pet food must be authorized under two of the EU legislature bodies. To learn more about labelling and regulations of pet food, see Pet food.
==== United Kingdom ==== The United Kingdom was the first European country with a Taco Bell. In 1986, a location was opened in London on Coventry Street (between Leicester Square and Piccadilly Circus) followed by a second location in Earl's Court near the Earl's Court tube station. One other store opened in Uxbridge but all closed in the mid-1990s. In 1994, the university food provider Compass announced plans for outlets on its university and college sites. However, only one store was opened at Birmingham University, which is now closed. After the Birmingham University branch closed, there were only two Taco Bell branches in the UK, at the Strategic Air Command and United States Air Force bases at RAF Mildenhall and RAF Lakenheath. Access is restricted to relevant service personnel. In the late 2000s, Yum! Brands announced that it was reopening Taco Bell locations in the United Kingdom as part of a large, planned expansion into Europe. Yum! took advantage of the recent great recession which led to increasing sales at other fast food outlets; it also said that there was now a greater awareness of Mexican food in the UK and that it can be successful with improved menu offerings and marketing. The first new store opened at the Lakeside Shopping Centre in Essex on June 28, 2010. Another store opened in Basildon, Essex, on November 29, 2010, and a third in the Manchester Arndale Food Court on November 7, 2011.
Sources: en.wikipedia.org
Degradation of Oligopeptide Sequences in N-(2-Hydroxypropyl)methacrylamide Copolymers by Bovine Spleen Cathepsin B". Die Makromolekulare Chemie 184, 2009–2020 (1983) K. Ulbrich, J. Strohalm, J. Kopeček, "Polymers Containing Enzymatically Degradable Bonds. 6. Hydrophilic Gels Cleavable by Chymotrypsin". Biomaterials 3, 150–154 (1982) J. Kopeček, P. Rejmanová, V. Chytrý, "Polymers Containing Enzymatically Degradable Bonds. 1. Chymotrypsin Catalyzed Hydrolysis of p-Nitroanilides of Phenylalanine and Tyrosine Attached to Side-Chains of Copolymers of N-(2-Hydroxypropyl)methacrylamide". Die Makromolekulare Chemie 182, 799–809 (1981) J. Kopeček, "Soluble Biomedical Polymers". Polymers in Medicine (Wroclaw) 7, 191–221 (1977) Z. Voldřich, Z. Tománek, J. Vacík, J. Kopeček, "Long-Term Experience with the Poly(Glycol Monomethacrylate) Gel in Plastic Operations of the Nose". Journal of Biomedical Materials Research 9, 675–685 (1975) J. Kopeček, H. Bažilová, Poly[N-(2-Hydroxypropyl)methacrylamide]. 1. "Radical Polymerization and Copolymerization". European Polymer Journal J. 9, 7–14 (1973) J. Kopeček, J. Vacík, D. Lím, "Permeability of Membranes Containing Ionogenic Groups". Journal of Polymer Science A-1, 9, 2801–2815 (1971) L. Šprincl, J. Kopeček, D. Lím, "Effect of Porosity of Heterogeneous Poly(Glycol Monomethacrylate) Gels on the Healing-in of Test Implants". Journal of Biomedical Materials Research 5, 447–458 (1971) J. Kopeček, J. Jokl, D. Lím, "Mechanism of Three-Dimensional Polymerization of Glycol Methacrylates" (in German). Journal of Polymer Science C 16, 3877–3889 (1968)
While Aβ has been implicated in cancer development, prompting studies on a variety of cancers to elucidate the nature of its possible effects, results are largely inconclusive. Aβ levels have been assessed in relation to a number of cancers, including esophageal, colorectal, lung, and hepatic, in response to observed reductions in risk for developing Alzheimer's disease in survivors of these cancers. All cancers were shown to be associated positively with increased Aβ levels, particularly hepatic cancers. This direction of association however has not yet been established. Studies focusing on human breast cancer cell lines have further demonstrated that these cancerous cells display an increased level of expression of amyloid precursor protein. Adults with Down syndrome had accumulation of amyloid in association with evidence of Alzheimer's disease, including declines in cognitive functioning, memory, fine motor movements, executive functioning, and visuospatial skills.
FASTpp measures the quantity of protein that resists digestion under various conditions. To this end, a thermostable protease is used, which cleaves specifically at exposed hydrophobic residues. The FASTpp assay combines the thermal unfolding, specificity of a thermostable protease for the unfolded fraction with the separation power of SDS-PAGE. Due to this combination, FASTpp can detect changes in the fraction folded over a large physico-chemical range of conditions including temperatures up to 85 °C, pH 6–9, presence or absence of the whole proteome. Applications range from biotechnology to study of point mutations and ligand binding assays. FASTpp has been used to probe: Lysate effect on protein stability Thermal proteome stability Coupled folding and binding Ligand effects on fraction folded & stability Effects of mutations on fraction folded & stability (e.g. point mutation/missense mutations) Kinetic protein stability
RVT-802 (allogeneic cultured postnatal thymus-derived tissue) is a medication being developed by Enzyvant Therapeutics Ireland Limited for the treatment of congenital athymia (absence of a thymus gland), especially in the context of DiGeorge syndrome. Enzyvant licensed the technology underlying RVT-802 from Duke University in 2017. In the same year, the Food and Drug Administration granted Regenerative Medicine Advanced Therapy – the second such approval ever to be granted – status to RVT-802. In December 2019, the Food and Drug Administration raised concerns about the manufacturing of RVT-802, and declined to approve it, instead issuing a Complete Response Letter. In April 2021, Enzyvant resubmitted its Biologics License Application. It is expected that the review of RVT-802 will conclude in October 2021 (PDUFA date).
Sources: en.wikipedia.org
SR9009 is a synthetic research compound that binds and modulates the nuclear receptors REV-ERBα and REV-ERBβ. It is used in laboratory studies of circadian biology and metabolism, not as an approved medicine. It is also known by the informal name Stenabolic.
No. SR9009 has not been approved as a therapeutic drug in the United States, European Union, or other major markets. Human safety and efficacy data are very limited. Its presence in consumer products does not imply regulatory approval.
The World Anti-Doping Agency lists SR9009 as a prohibited substance because it can alter gene expression and metabolic pathways relevant to performance. The ban applies at all times, not only during competition. Detection relies on laboratory methods such as mass spectrometry.
SR9009 is a synthetic research compound that activates the REV-ERBα and REV-ERBβ nuclear receptors. It is not an approved drug and has no established human therapeutic use. Most published biological data come from cell and rodent studies.